Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 19 August 2014 | By Alexander Gaffney, RAC,
For at least the 12th time since May 2013, the US Food and Drug Administration (FDA) has sent a Warning Letter to an Indian pharmaceutical manufacturer accusing it of falsifying data used to support the ongoing approval of its drug products.
For more on Indian Companies' data integrity problems, please see our updated tracker tool here.
The company, Marck Biosciencies, was subject to an October-November 2013 inspection by FDA at its Kheda, India manufacturing facility.
There, FDA said it found troubling deficiencies, including that the company generated unofficial “visual inspection records” that contained data that were "different from the official batch records reviewed by [Marck's] quality unit."
FDA said a review of those records showed that the products often contained "significantly more quality defects" than the official records indicated. For example, official records only indicated that 18 units of a drug batch failed to meet specifications, whereas the total number was actually 200. FDA said the company was unable to prove that all units had been rejected from further processing.
In other cases, FDA found Marck to be using "scratch paper" (i.e. "scrap paper") to record "critical manufacturing data." Those data did not always match the official records, FDA alleged, implying that the data were later altered to be more favorable.
"The use of unofficial and scratch paper records is not acceptable current good manufacturing practices (CGMP)," FDA wrote.
In another alarming instance, FDA said that its inspectors interviewed Marck employees who admitted that certain activities recorded as having been performed were in fact falsified, and had never been performed. "Specifically, [Marck's] head of production reported to our investigator that he completes 'in process quality assurance check' fields in the batch record but does not actually perform the listed operations," FDA wrote.
In another notable example, FDA said it found evidence that the company had "falsified documents designed to demonstrate the effectiveness of CGMP training." The company had filled out in advance the answers to an exam designed to assess knowledge of federal regulations, FDA alleged. Further, "that a senior manager was engaged in the falsification of documents is troubling and raises questions about validity of documents generated by your firm," FDA noted.
Elsewhere, FDA inspectors said they found "significant mold growth" in an on-site washroom located "at the entry of the sterile manufacturing area." The mold growth was apparently so bad that the room had partially "caved in." This was especially concerning given a recent finding by the UK's Medicines and Healthcare Products regulatory Agency (MHRA) which found fungal growth in one of the facility's parenteral products, FDA said.
Regulators also found "numerous dead insects" throughout the facility and "dead and decaying frogs" near the facility's exit dock. The facility is reportedly situated near a "swamp-like perimeter," FDA noted.
The facility was advised to implement a corrective action plan and to hire a third-party auditor to ensure organizational compliance.
FDA Warning Letter
Tags: Data Falsification, Data Integrity, Warning Letter
Regulatory Focus newsletters
All the biggest regulatory news and happenings.